|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q51055350
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241120235917.0 |
|
008
|
|
|
241120nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q51055350
|
|
024
|
|
|
‡a
0000-0003-4031-7339
‡2
orcid
|
|
024
|
|
|
‡a
40161009800
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q51055350
|
|
100
|
0 |
|
‡a
Francisco Batel Marques
‡9
ast
‡9
es
‡9
sl
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
Francisco Batel Marques
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Francisco Batel Marques
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A comparison between two recommendations to conduct and report systematic reviews on drug's safety
|
|
670
|
|
|
‡a
Author's A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
|
|
670
|
|
|
‡a
Author's A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.
|
|
670
|
|
|
‡a
Author's A systematic review of observational studies evaluating costs of adverse drug reactions
|
|
670
|
|
|
‡a
Author's A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs
|
|
670
|
|
|
‡a
Author's An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review
|
|
670
|
|
|
‡a
Author's Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis
|
|
670
|
|
|
‡a
Author's Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database
|
|
670
|
|
|
‡a
Author's Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
|
|
670
|
|
|
‡a
Author's Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital
|
|
670
|
|
|
‡a
Author's Methodologic Assessment of the Systematic Reviews of Ophthalmic Adverse Drug Reactions Published in Ophthalmology Journals: A Systematic Review
|
|
670
|
|
|
‡a
Author's [Monitoring antibiotic consumption in the surgery and orthopaedics]
|
|
670
|
|
|
‡a
Author's Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
|
|
670
|
|
|
‡a
Author's Number needed to treat (NNT) in clinical literature: an appraisal.
|
|
670
|
|
|
‡a
Author's Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports.
|
|
670
|
|
|
‡a
Author's Outcomes From the First 6 Years of Operation of the Central Portugal Pharmacovigilance Unit.
|
|
670
|
|
|
‡a
Author's Pharmacovigilance in Portugal: Activity of the Central Pharmacovigilance Unit
|
|
670
|
|
|
‡a
Author's Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis
|
|
670
|
|
|
‡a
Author's Recommendations to conduct and report systematic reviews in medical literature: a scoping review
|
|
670
|
|
|
‡a
Author's Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients
|
|
670
|
|
|
‡a
Author's Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis
|
|
670
|
|
|
‡a
Author's Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis.
|
|
670
|
|
|
‡a
Author's Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data.
|
|
670
|
|
|
‡a
Author's Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.
|
|
670
|
|
|
‡a
Author's Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
|
|
670
|
|
|
‡a
Author's Statins and risk of cataracts: A systematic review and meta-analysis of observational studies
|
|
670
|
|
|
‡a
Author's Testing the usefulness of the number needed to treat to be harmed
|
|
670
|
|
|
‡a
Author's Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
|
|
670
|
|
|
‡a
Author's The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review
|
|
909
|
|
|
‡a
(scopus) 40161009800
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000340317339
‡9
1
|
|
919
|
|
|
‡a
testingtheusefulnessofthenumberneededtotreattobeharmednnthinbenefitriskevaluationscasestudywithmedicineswithdrawnfromtheeuropeanmarketduetosafetyreasons
‡A
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons
‡9
1
|
|
919
|
|
|
‡a
benefitofher2targetedtherapiesonoverallsurvivalofpatientswithmetastaticher2positivebreastcancerasystematicreview
‡A
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review
‡9
1
|
|
919
|
|
|
‡a
testingtheusefulnessofthenumberneededtotreattobeharmed
‡A
Testing the usefulness of the number needed to treat to be harmed
‡9
1
|
|
919
|
|
|
‡a
statinsandriskofcataractsasystematicreviewandmetaanalysisofobservationalstudies
‡A
Statins and risk of cataracts: A systematic review and meta-analysis of observational studies
‡9
1
|
|
919
|
|
|
‡a
safetyprofilesofadalimumabetanerceptandinfliximabapharmacovigilancestudyusingameasureofdisproportionalityinadatabaseofspontaneouslyreportedadverseevents
‡A
Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
‡9
1
|
|
919
|
|
|
‡a
safetyofbiologicsapprovedfortreatingrheumatoidarthritisanalysisofspontaneousreportsofadverseevents
‡A
Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events.
‡9
1
|
|
919
|
|
|
‡a
safetymonitoringofophthalmicbiologicsasystematicreviewofpreandpostmarketingsafetydata
‡A
Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data.
‡9
1
|
|
919
|
|
|
‡a
riskofophthalmicadverseeffectsinpatientstreatedwithmekinhibitorsasystematicreviewandmetaanalysis
‡A
Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis.
‡9
1
|
|
919
|
|
|
‡a
riskofnonarteriticischaemicopticneuropathywithphosphodiesterasetype5inhibitorsasystematicreviewandmetaanalysis
‡A
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysis
‡9
1
|
|
919
|
|
|
‡a
rectussheathhematomainpatientsreceivingsubcutaneousenoxaparinacaseseriesof5patients
‡A
Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients
‡9
1
|
|
919
|
|
|
‡a
recommendationstoconductandreportsystematicreviewsinmedicalliteratureascopingreview
‡A
Recommendations to conduct and report systematic reviews in medical literature: a scoping review
‡9
1
|
|
919
|
|
|
‡a
prevalenceofundiagnosedhypothyroidismineuropeasystematicreviewandmetaanalysis
‡A
Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis
‡9
1
|
|
919
|
|
|
‡a
pharmacovigilanceinportugalactivityofthecentralpharmacovigilanceunit
‡A
Pharmacovigilance in Portugal: Activity of the Central Pharmacovigilance Unit
‡9
1
|
|
919
|
|
|
‡a
outcomesfromthe16yearsofoperationofthecentralportugalpharmacovigilanceunit
‡A
Outcomes From the First 6 Years of Operation of the Central Portugal Pharmacovigilance Unit.
‡9
1
|
|
919
|
|
|
‡a
nursesspontaneousreportingofadversedrugreactionsexpertreviewofroutinereports
‡A
Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports.
‡9
1
|
|
919
|
|
|
‡a
numberneededtotreatnntinclinicalliteratureanappraisal
‡A
Number needed to treat (NNT) in clinical literature: an appraisal.
‡9
1
|
|
919
|
|
|
‡a
numberneededtoharminthepostmarketingsafetyevaluationresultsforrosiglitazoneandpioglitazone
‡A
Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone
‡9
1
|
|
919
|
|
|
‡a
monitoringantibioticconsumptioninthesurgeryandorthopaedics
‡A
[Monitoring antibiotic consumption in the surgery and orthopaedics]
‡9
1
|
|
919
|
|
|
‡a
methodologicassessmentofthesystematicreviewsofophthalmicadversedrugreactionspublishedinophthalmologyjournalsasystematicreview
‡A
Methodologic Assessment of the Systematic Reviews of Ophthalmic Adverse Drug Reactions Published in Ophthalmology Journals: A Systematic Review
‡9
1
|
|
919
|
|
|
‡a
intensivesafetymonitoringprogramofantineoplasticmedicinesapilotstudyinaportugueseoncologyhospital
‡A
Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital
‡9
1
|
|
919
|
|
|
‡a
effectivenessinclinicalpracticeversusefficacyofdipeptidylpeptidase4inhibitorsinclinicaltrialsfortype2diabetesprotocolforsystematicreview
‡A
Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
‡9
1
|
|
919
|
|
|
‡a
druginducedhypersensitivitya5yearretrospectivestudyinahospitalelectronichealthrecordsdatabase
‡A
Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database
‡9
1
|
|
919
|
|
|
‡a
benefitriskoftherapiesforrelapsingremittingmultiplesclerosistestingthenumberneededtotreattobenefitnntbnumberneededtotreattoharmnnthandthelikelihoodtobehelpedorharmedlhhasystematicreviewandmetaanalysis
‡A
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis
‡9
1
|
|
919
|
|
|
‡a
analysisoftheeffectivenessoutcomesofeconomicstudiesevaluatingophthalmicdrugsasystematicreview
‡A
An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review
‡9
1
|
|
919
|
|
|
‡a
systematicreviewofthemethodologicalqualityofeconomicstudiesevaluatingophthalmicdrugs
‡A
A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs
‡9
1
|
|
919
|
|
|
‡a
systematicreviewofobservationalstudiesevaluatingcostsofadversedrugreactions
‡A
A systematic review of observational studies evaluating costs of adverse drug reactions
‡9
1
|
|
919
|
|
|
‡a
systematicreviewandmetaanalysisoftheassociationbetweensystemicfluoroquinolonesandretinaldetachment
‡A
A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment.
‡9
1
|
|
919
|
|
|
‡a
metaanalysisofseriousadverseeventsreportedwithexenatideandliraglutideacutepancreatitisandcancer
‡A
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
‡9
1
|
|
919
|
|
|
‡a
comparisonbetween2recommendationstoconductandreportsystematicreviewsondrugssafety
‡A
A comparison between two recommendations to conduct and report systematic reviews on drug's safety
‡9
1
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
ISNI|0000000066816708
|
|
996
|
|
|
‡2
PTBNP|1652764
|
|
996
|
|
|
‡2
BLBNB|000993246
|
|
996
|
|
|
‡2
BNE|XX914135
|
|
996
|
|
|
‡2
LC|no2012049750
|
|
996
|
|
|
‡2
PTBNP|1390272
|
|
996
|
|
|
‡2
BNE|XX1723565
|
|
996
|
|
|
‡2
SUDOC|06720581X
|
|
996
|
|
|
‡2
NTA|074617516
|
|
996
|
|
|
‡2
SUDOC|160180007
|
|
996
|
|
|
‡2
PTBNP|276310
|
|
996
|
|
|
‡2
SUDOC|086183214
|
|
996
|
|
|
‡2
ISNI|000000007042546X
|
|
996
|
|
|
‡2
ISNI|0000000068213863
|
|
996
|
|
|
‡2
PTBNP|1478483
|
|
996
|
|
|
‡2
SUDOC|248522205
|
|
996
|
|
|
‡2
ISNI|0000000070247886
|
|
996
|
|
|
‡2
SUDOC|272422266
|
|
996
|
|
|
‡2
ISNI|0000000041025846
|
|
996
|
|
|
‡2
PTBNP|1722399
|
|
996
|
|
|
‡2
ISNI|0000000040416394
|
|
996
|
|
|
‡2
PTBNP|1909775
|
|
996
|
|
|
‡2
BLBNB|001192567
|
|
996
|
|
|
‡2
PTBNP|240857
|
|
996
|
|
|
‡2
DNB|1056211857
|
|
996
|
|
|
‡2
BLBNB|000271021
|
|
996
|
|
|
‡2
DNB|1122699522
|
|
996
|
|
|
‡2
ISNI|0000000082850930
|
|
996
|
|
|
‡2
LC|n 97008711
|
|
996
|
|
|
‡2
PTBNP|1660015
|
|
996
|
|
|
‡2
ISNI|0000000369635138
|
|
996
|
|
|
‡2
ISNI|0000000510953451
|
|
996
|
|
|
‡2
DNB|1057455083
|
|
996
|
|
|
‡2
BLBNB|000701137
|
|
996
|
|
|
‡2
ISNI|0000000073256032
|
|
996
|
|
|
‡2
PTBNP|1184380
|
|
996
|
|
|
‡2
PTBNP|1769081
|
|
996
|
|
|
‡2
BNC|981058527266606706
|
|
996
|
|
|
‡2
PTBNP|89776
|
|
996
|
|
|
‡2
LC|n 2009014501
|
|
996
|
|
|
‡2
BLBNB|000289493
|
|
996
|
|
|
‡2
LC|n 2004093994
|
|
996
|
|
|
‡2
BNE|XX6330066
|
|
996
|
|
|
‡2
BNF|12968253
|
|
996
|
|
|
‡2
DNB|173168582
|
|
996
|
|
|
‡2
J9U|987007386754505171
|
|
996
|
|
|
‡2
DNB|1147406650
|
|
996
|
|
|
‡2
BLBNB|000445452
|
|
996
|
|
|
‡2
BNC|981058609684006706
|
|
996
|
|
|
‡2
BNC|981060413527206706
|
|
996
|
|
|
‡2
SUDOC|158659473
|
|
996
|
|
|
‡2
DNB|1050803272
|
|
996
|
|
|
‡2
BNE|XX1081950
|
|
996
|
|
|
‡2
BLBNB|001498758
|
|
996
|
|
|
‡2
PTBNP|82595
|
|
996
|
|
|
‡2
SUDOC|233647953
|
|
996
|
|
|
‡2
NTA|184847206
|
|
996
|
|
|
‡2
DNB|1265427321
|
|
996
|
|
|
‡2
SUDOC|143102923
|
|
996
|
|
|
‡2
BNC|981058525555206706
|
|
996
|
|
|
‡2
BNE|XX5573808
|
|
996
|
|
|
‡2
PTBNP|1715292
|
|
996
|
|
|
‡2
ISNI|0000000060264164
|
|
996
|
|
|
‡2
BNE|XX1528752
|
|
996
|
|
|
‡2
ISNI|000000038856622X
|
|
996
|
|
|
‡2
PTBNP|1462733
|
|
996
|
|
|
‡2
PTBNP|1020517
|
|
996
|
|
|
‡2
PTBNP|1850529
|
|
996
|
|
|
‡2
NTA|216888247
|
|
996
|
|
|
‡2
BLBNB|000288013
|
|
996
|
|
|
‡2
LC|n 2015210047
|
|
996
|
|
|
‡2
ISNI|0000000116430994
|
|
996
|
|
|
‡2
LC|n 97910555
|
|
996
|
|
|
‡2
DNB|1057379670
|
|
996
|
|
|
‡2
PTBNP|122458
|
|
996
|
|
|
‡2
PTBNP|1763968
|
|
996
|
|
|
‡2
ISNI|0000000069923250
|
|
996
|
|
|
‡2
PTBNP|226214
|
|
996
|
|
|
‡2
NTA|436965577
|
|
996
|
|
|
‡2
PTBNP|1212448
|
|
996
|
|
|
‡2
LC|n 95922753
|
|
996
|
|
|
‡2
LC|n 50045135
|
|
996
|
|
|
‡2
ISNI|0000000068999659
|
|
996
|
|
|
‡2
ISNI|0000000082513256
|
|
996
|
|
|
‡2
DNB|1057362530
|
|
996
|
|
|
‡2
PTBNP|1052181
|
|
996
|
|
|
‡2
LC|n 95004713
|
|
996
|
|
|
‡2
BLBNB|000187369
|
|
996
|
|
|
‡2
JPG|500030716
|
|
996
|
|
|
‡2
ISNI|0000000066399289
|
|
996
|
|
|
‡2
BLBNB|001637197
|
|
996
|
|
|
‡2
BNE|XX858616
|
|
996
|
|
|
‡2
ISNI|0000000070207673
|
|
996
|
|
|
‡2
ISNI|0000000060565848
|
|
996
|
|
|
‡2
ISNI|0000000069321006
|
|
996
|
|
|
‡2
DNB|1281280496
|
|
996
|
|
|
‡2
BNF|17074986
|
|
996
|
|
|
‡2
ISNI|0000000068784041
|
|
996
|
|
|
‡2
BNC|981058527262606706
|
|
996
|
|
|
‡2
ISNI|000000006948469X
|
|
996
|
|
|
‡2
ISNI|000000007040401X
|
|
996
|
|
|
‡2
ISNI|0000000445342346
|
|
996
|
|
|
‡2
RERO|A018711268
|
|
996
|
|
|
‡2
LC|n 2015235633
|
|
996
|
|
|
‡2
ISNI|0000000067646659
|
|
996
|
|
|
‡2
BLBNB|001573974
|
|
996
|
|
|
‡2
ISNI|0000000393014796
|
|
996
|
|
|
‡2
ISNI|0000000069787463
|
|
996
|
|
|
‡2
PTBNP|1389469
|
|
996
|
|
|
‡2
PTBNP|1930851
|
|
996
|
|
|
‡2
ISNI|0000000070334816
|
|
996
|
|
|
‡2
LC|n 2005203874
|
|
996
|
|
|
‡2
DNB|11678962X
|
|
996
|
|
|
‡2
BNF|18070906
|
|
996
|
|
|
‡2
SUDOC|078229154
|
|
996
|
|
|
‡2
PTBNP|828938
|
|
996
|
|
|
‡2
LC|n 86853770
|
|
996
|
|
|
‡2
LC|no2014088498
|
|
996
|
|
|
‡2
J9U|987007440246105171
|
|
996
|
|
|
‡2
DNB|140057099
|
|
996
|
|
|
‡2
LC|n 2020250363
|
|
996
|
|
|
‡2
PTBNP|231521
|
|
996
|
|
|
‡2
DNB|1050624947
|
|
996
|
|
|
‡2
ISNI|0000000078268948
|
|
996
|
|
|
‡2
BLBNB|001017692
|
|
996
|
|
|
‡2
RERO|A018058010
|
|
996
|
|
|
‡2
PTBNP|528204
|
|
996
|
|
|
‡2
PTBNP|1088370
|
|
996
|
|
|
‡2
BLBNB|000627706
|
|
996
|
|
|
‡2
ISNI|0000000035300012
|
|
996
|
|
|
‡2
SUDOC|180555502
|
|
996
|
|
|
‡2
LC|no 88001981
|
|
996
|
|
|
‡2
SUDOC|085921556
|
|
996
|
|
|
‡2
NII|DA14541417
|
|
996
|
|
|
‡2
ISNI|000000003150910X
|
|
996
|
|
|
‡2
PTBNP|1891459
|
|
996
|
|
|
‡2
JPG|500039460
|
|
996
|
|
|
‡2
BNE|XX846683
|
|
996
|
|
|
‡2
BLBNB|001526236
|
|
996
|
|
|
‡2
BLBNB|000569938
|
|
996
|
|
|
‡2
PTBNP|130642
|
|
996
|
|
|
‡2
ISNI|0000000428294661
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
